Evidence map›Paper›PMID 34386493›Full record

ArticleFrontiers in cell and developmental biology2021

Surface PEGylated Cancer Cell Membrane-Coated Nanoparticles for Codelivery of Curcumin and Doxorubicin for the Treatment of Multidrug Resistant Esophageal Carcinoma.

Yi Gao, Yue Zhu, Xiaopeng Xu, Fangjun Wang, Weidong Shen, Xia Leng, Jiyi Zhao, Bingtuan Liu, Yangyun Wang, Pengfei Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yi GaoDepartment of Gastroenterology, The Affiliated Jiangyin Hospital of Xuzhou Medical University, Jiangyin, China.
Yue ZhuDepartment of Gastroenterology, The Affiliated Jiangyin Hospital of Xuzhou Medical University, Jiangyin, China.
Xiaopeng XuDepartment of Gastroenterology, The Affiliated Jiangyin Hospital of Xuzhou Medical University, Jiangyin, China.
Fangjun WangDepartment of Gastroenterology, The Affiliated Jiangyin Hospital of Xuzhou Medical University, Jiangyin, China.
Weidong ShenDepartment of Gastroenterology, The Affiliated Jiangyin Hospital of Xuzhou Medical University, Jiangyin, China.
Xia LengDepartment of Gastroenterology, The Affiliated Jiangyin Hospital of Xuzhou Medical University, Jiangyin, China.
Jiyi ZhaoDepartment of Gastroenterology, The Affiliated Jiangyin Hospital of Xuzhou Medical University, Jiangyin, China.
Bingtuan LiuDepartment of Gastroenterology, The Affiliated Jiangyin Hospital of Xuzhou Medical University, Jiangyin, China.
Yangyun WangState Key Laboratory of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, China.
Pengfei LiuDepartment of Gastroenterology, The Affiliated Jiangyin Hospital of Xuzhou Medical University, Jiangyin, China.
Xuzhou Medical College · CNJiangyin People's Hospital · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe emergence of multi-drug resistance (MDR) in esophageal carcinoma has severely affected the effect of chemotherapy and shortened the survival of patients. To this end, we intend to develop a biomimetic nano-targeting drug modified by cancer cell membrane, and investigate its therapeutic effect.

methodsThe degradable poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) co-loaded with doxorubicin (DOX) and curcumin (Cur) were prepared by solvent evaporation method. TE10 cell membrane and Distearoyl phosphatidylethanolamine-polyethylene glycol (DSPE-PEG) were then coated on the PLGA NPs by membrane extrusion to prepare the PEG-TE10@PLGA@DOX-Cur NPs (PMPNs). Size and zeta potential of the PMPNs were analyzed by lazer particle analyzer, and the morphology of PMPNs was observed by transmission electron microscope. The TE10 cell membrane protein on PMPNs was analyzed by gel electrophoresis. The DOX-resistant esophageal cancer cell model TE10/DOX was established through high-dose induction. The

resultsThe prepared cell membrane coated PMPNs had a regular spherical structure with an average diameter of 177 nm. PMPNs could directly target TE10 and TE10/DOX cells or TE10/DOX xenografted tumor and effectively inhibit the growth of DOX-resistant esophageal carcinoma. Besides, the PMPNs was confirmed to have high biosafety.

conclusionIn this study, a targeted biomimetic nano-drug delivery system PMPNs was successfully prepared, which overcome the MDR of esophageal carcinoma by co-delivering DOX and sensitizer curcumin.

Indexed as

curcumindoxorubicinesophageal carcinomahomologous targetingmultidrug resistant

Identifiers

PMID34386493
PMCPMC8353447
OpenAlexW3183842640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.